175033-36-0
Chemical Structure
Nitroaspirin
Synonym(s): NCX 4016
- CAS No.: 175033-36-0
- Formula:C16H13NO7
- Molecular Weight:331.28
IUPAC Name: 3-((nitrooxy)methyl)phenyl 2-acetoxybenzoate
InChIKey: IOJUJUOXKXMJNF-UHFFFAOYSA-N
SMILES: O=C(OC1=CC=CC(CO[N+]([O-])=O)=C1)C2=CC=CC=C2OC(C)=O
Biological Activity: Nitroaspirin (NCX 4016) is an orally active ARG1 and NOS2 inhibitor. Nitroaspirin reduces ARG1 enzyme activity through a STAT6-mediated signaling pathway and feedback-inhibits the catalytic activity of NOS2 in a manner dependent on the NO-releasing group. Nitroaspirin continuously releases intracellular NO, thereby inducing redox-dependent loss of cell viability. Nitroaspirin also inhibits COX (IC50 of 68 μM for oCOX-1), exerting antithrombotic and anti-inflammatory effects, and effectively inhibits the proliferation of Cisplatin (HY-17394)-resistant human ovarian cancer cells. Nitroaspirin is useful for research on colon cancer, breast cancer, and cisplatin-resistant human ovarian cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nitroaspirin | 98.57% | Nitroaspirin (NCX 4016) is an orally active ARG1 and NOS2 inhibitor. Nitroaspirin reduces ARG1 enzyme activity through a STAT6-mediated signaling pathway and feedback-inhibits the catalytic activity of NOS2 in a manner dependent on the NO-releasing group. Nitroaspirin continuously releases intracellular NO, thereby inducing redox-dependent loss of cell viability. Nitroaspirin also inhibits COX (IC50 of 68 μM for oCOX-1), exerting antithrombotic and anti-inflammatory effects, and effectively inhibits the proliferation of Cisplatin (HY-17394)-resistant human ovarian cancer cells. Nitroaspirin is useful for research on colon cancer, breast cancer, and cisplatin-resistant human ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. De Santo C, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America. 2005 Mar 15;102(11):4185-90. [Content Brief]
- [2]. Parinandi NL, et al. Nitroaspirin (NCX-4016), an NO donor, is antiangiogenic through induction of loss of redox-dependent viability and cytoskeletal reorganization in endothelial cells. Antioxidants & redox signaling. 2007 Nov;9(11):1837-49. [Content Brief]
- [3]. Corazzi T, et al. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7. [Content Brief]
